Pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90075/1/phco.29.7.822.pd

Precision Pharmacotherapy Enables Precision Medicine

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138280/1/phar1998_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138280/2/phar1998.pd

The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/115979/1/phar1640.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/115979/2/phar1640_am.pd

Antipsychotic‐Induced Hyperprolactinemia

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64.pd

Implementing and evaluating virtual patient cases within a team‐based learning pedagogy in a therapeutics course sequence

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/1/jac51053.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/2/jac51053_am.pd

An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder

BackgroundSecond generation antipsychotic (SGA) use in bipolar disorder is common and has proven effective in short‐term trials. There continues to be a lack of understanding of the mechanisms underlying many of their positive and negative effects in bipolar disorder. This study aimed to describe the metabolite profiles of bipolar subjects treated with SGAs by comparing to metabolite profiles of bipolar subjects treated with lithium, and schizophrenia subjects treated with SGAs.MethodsCross‐sectional, fasting untargeted serum metabolomic profiling was conducted in 82 subjects diagnosed with bipolar I disorder (n = 30 on SGAs and n = 32 on lithium) or schizophrenia (n = 20). Metabolomic profiles of bipolar subjects treated with SGAs were compared to bipolar subjects treated with lithium and schizophrenia subjects treated with SGAs using multivariate methods.ResultsPartial lease square discriminant analysis (PLS‐DA) plots showed separation between bipolar subjects treated with SGAs, bipolar subjects treated with lithium, or schizophrenia subjects treated with SGAs. Top influential metabolite features were associated with several pathways including that of polyunsaturated fatty acids, pyruvate, glucose, and branched chain amino acids.ConclusionsThe findings from this study require further validation in pre‐ and posttreated bipolar and schizophrenia subjects, but suggest that the pharmacometabolome may be diagnosis specific.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/115928/1/cts12324.pd

Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138379/1/phar1968_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138379/2/phar1968.pd

Gene‐specific DNA methylation may mediate atypical antipsychotic‐induced insulin resistance

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134192/1/bdi12422_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/134192/2/bdi12422.pd

Identification of non‐reported bupropion metabolites in human plasma

Bupropion and its three active metabolites exhibit clinical efficacy in the treatment of major depression, seasonal depression and smoking cessation. The pharmacokinetics of bupropion in humans is highly variable. It is not known if there are any non‐reported metabolites formed in humans in addition to the three known active metabolites. This paper reports newly identified and non‐reported metabolites of bupropion in human plasma samples. Human subjects were dosed with a single oral dose of 75 mg of an immediate release bupropion HCl tablet. Plasma samples were collected and analysed by LC–MS/MS at 0, 6 and 24 h. Two non‐reported metabolites (M1 and M3) were identified with mass‐to‐charge (m/z) ratios of 276 (M1, hydration of bupropion) and 258 (M3, hydroxylation of threo/erythrohydrobupropion) from human plasma in addition to the known hydroxybupropion, threo/erythrohydrobupropion and the glucuronidation products of the major metabolites (M2 and M4–M7). These new metabolites may provide new insight and broaden the understanding of bupropion’s variability in clinical pharmacokinetics. © 2016 The Authors Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134787/1/bdd2046_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/134787/2/bdd2046.pd

Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90038/1/phco.31.8.806.pd